Does JSPR pay a dividend?

The cached stock data on this page does not show a positive dividend yield for JSPR. Dividend status can change, so verify the latest company filings before relying on income assumptions.

What does JSPR stock do?

Pre-revenue clinical-stage biotechnology company focused on developing briquilimab (a monoclonal antibody targeting CD117/c-Kit) for mast cell-driven diseases and stem cell conditioning.

What is JSPR stock's price target?

This cached page does not contain a precise model fair value for JSPR.

The TradeMates model verdict for JSPR is AVOID with an investment score of 25/100. Treat this as a model signal to review, not a personal buy recommendation.

Is JSPR a good dividend stock?

JSPR is not presented as a dividend idea on this cached TradeMates page because no positive dividend yield is available in the cached data.

JSPR (JSPR) Stock Analysis

Q: Is JSPR stock a good investment?

The cached TradeMates AI model rates JSPR as AVOID with an investment score of 25/100. The model evaluates Jasper Therapeutics (JSPR) as AVOID due to severe cash burn, imminent dilution risk within a estimated 4.5-month cash runway, and negative analyst revisions. This is algorithmic model output, not personal investment advice.

Verdict: AVOID

Severe cash burn creates an urgent 4.5-month runway crisis for briquilimab, driving acute dilution risk despite pipeline optionality.

Investment score: 25/100

The model evaluates Jasper Therapeutics (JSPR) as AVOID due to severe cash burn, imminent dilution risk within a estimated 4.5-month cash runway, and negative analyst revisions.

View the full interactive analysis